1.59
price down icon3.64%   -0.06
after-market Dopo l'orario di chiusura: 1.65 0.06 +3.77%
loading

Perché le azioni Aclaris Therapeutics Inc (ACRS) sono in ribasso?

Abbiamo notato un calo di 9.29% nelle azioni di Aclaris Therapeutics Inc (ACRS) durante la sessione di negoziazione di 2025-03-10. Sebbene ciò possa essere attribuito alla normale volatilità o a vari fattori interni ed esterni, tieni presente che stiamo monitorando attivamente la situazione e forniremo aggiornamenti tempestivi il prima possibile!
2023-11-13:

Aclaris Therapeutics Stock (ACRS) dropped by 86.44% from $4.755 to $0.6449 in the trading on Monday November 13, 2023. The reason why ACRS stock down today is due to topline results from a Phase 2b study of zunsemetinib (ATI-450) in subjects with moderate to severe rheumatoid arthritis.

  • Citing topline data at 12 weeks, patients who received either 20mg or 50mg doses of oral zunsemetinib didn’t meet the main endpoint called ACR20 or any secondary endpoints.
  • Based on the overall program results, Aclaris will discontinue further development of the ATI-450 program, including halting enrollment of Aclaris' ongoing Phase 2a trial of zunsemetinib in psoriatic arthritis.
$144.50
price up icon 3.20%
diagnostics_research DGX
$166.42
price down icon 1.03%
diagnostics_research LH
$236.83
price down icon 1.01%
diagnostics_research WAT
$373.13
price down icon 1.51%
diagnostics_research MTD
$1,216.02
price down icon 2.18%
diagnostics_research IQV
$185.42
price up icon 1.06%
Capitalizzazione:     |  Volume (24 ore):